A recent review investigated risk factors for preeclampsia in early pregnancy, finding that antiphospholipid antibody syndrome may be the strongest risk factor. As a result of these findings, researchers have compiled a list of risk factors to help clinicians determine which women are more likely to develop the condition and aid them in weighing treatment options…
The problem that dogs the work of all of those treating patients with antiphospholipid syndrome (APS) is the apparent lack of knowledge of the syndrome, both by the general public, as well as by swaths of the medical fraternity. Perhaps it was ever thus—a syndrome less than 40 years old could be described as new,…
Michael Lockshin, MD, reminds medical professionals that patients suffering from antiphospholipid syndrome (APS) don’t respond to medications in the same way as patients with other clotting-related diseases. Insufficient evidence exists to determine whether the new wave of anticoagulant medications is safe for use in patients with APS…
Antiphospholipid syndrome (APS) is an autoimmune condition characterized by hypercoagulability often manifested as recurrent thrombosis or pregnancy complications, with persistently circulating antiphospholipid (aPL) antibodies or lupus anticoagulant. Catastrophic APS (CAPS), also known as Asherson syndrome, occurs in less than 1% of cases of APS and involves occlusive microangiopathy in at least three organ systems.1 Case…
Research around autoimmune disorder shows patients may respond to treatment with sirolimus
Sarah Troxell, RN, BSN, imparts what she’s learned about RA and medication management, assembling a team of health professionals and battling other health issues
With a wide range of clinical manifestations and frequent occurrence among rheumatology patients, APS is one for rheumatologists to watch
Why rheumatologists must coin simple, comprehensible terms for what we read, speak and write to our patients
Successes, challenges, and controversies of diagnostic methods for APS
APS ACTION is coordinating international efforts to study this rare and potentially fatal autoimmune disorder